Your browser doesn't support javascript.
loading
MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study.
Zhang, Qing Yuan; Sun, Tao; Yin, Yong Mei; Li, Hui Ping; Yan, Min; Tong, Zhong Sheng; Oppermann, Christina P; Liu, Yun Peng; Costa, Romulo; Li, Man; Cheng, Ying; Ouyang, Qu Chang; Chen, Xi; Liao, Ning; Wu, Xin Hong; Wang, Xiao Jia; Feng, Ji Feng; Hegg, Roberto; Kanakasetty, G B; Coccia-Portugal, Maria A; Han, Ru Bing; Lu, Yi; Chi, Hai Dong; Jiang, Ze Fei; Hu, Xi Chun.
Afiliação
  • Zhang QY; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Sun T; Department of Medical Oncology, Cancer Hospital of China Medical University/ Liaoning Cancer Hospital, Shenyang, China.
  • Yin YM; Department of Oncology, Jiangsu Province Hospital, Nanjing, China.
  • Li HP; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Yan M; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Tong ZS; Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Oppermann CP; Centro de Pesquisa Clínica de Oncologia e Hematologia, Hospital Mãe de Deus/AESC, Porto Alegre, Brazil.
  • Liu YP; Department of Medical Oncology, First Affiliated Hospital of China Medical University,Shenyang, China.
  • Costa R; Oncologia Clínica, Instituto do Cancer do Estado de São Paulo - ICESP, São Paulo, Brazil.
  • Li M; Department of Oncology, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Cheng Y; Department of Medical Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
  • Ouyang QC; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China.
  • Chen X; Department of Medical Oncology, Fuzhou General Hospital of Nanjing Military Command, Fuzhou, China.
  • Liao N; Department of Breast Cancer, Guangdong General Hospital, Guangzhou, China.
  • Wu XH; Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China.
  • Wang XJ; Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Feng JF; Department of Medical Oncology, Jiangsu Province Cancer Hospital, Nanjing, China.
  • Hegg R; Department of Gynecology and Obstetrics, Hospital Pérola Byington and FMUSP, São Paulo-SP, Brazil.
  • Kanakasetty GB; Department of Medical Oncology, HCG Hospitals and Kidwai Memorial Institute of Oncology, Bangalore, India.
  • Coccia-Portugal MA; Clinical Trial Department, Eastleigh Breast Care Center, Pretoria, South Africa.
  • Han RB; Eli Lilly and Company, Shanghai, China.
  • Lu Y; Eli Lilly and Company, Indianapolis, IN, United States of America.
  • Chi HD; Eli Lilly and Company, Shanghai, China.
  • Jiang ZF; Department of Breast Cancer, Fifth Medical Center of Chinese PLA General Hospital, 100 West Fourth Ring Middle Road, Beijing 100071, China.
  • Hu XC; Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai 200032, China.
Ther Adv Med Oncol ; 12: 1758835920963925, 2020.
Article em En | MEDLINE | ID: mdl-33149768
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article